These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 2467015)

  • 41. Quisqualis indica Improves Benign Prostatic Hyperplasia by Regulating Prostate Cell Proliferation and Apoptosis.
    Ub Wijerathne C; Park HS; Jeong HY; Song JW; Moon OS; Seo YW; Won YS; Son HY; Lim JH; Yeon SH; Kwun HJ
    Biol Pharm Bull; 2017 Dec; 40(12):2125-2133. PubMed ID: 28943529
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Insulin-like growth factor-1 is associated with regulation of the luteinizing hormone production in men receiving androgen deprivation therapy with gonadotropin-releasing hormone analogues for localized prostate cancer.
    Hara N; Takizawa I; Isahaya E; Nishiyama T; Hoshii T; Ishizaki F; Takahashi K
    Urol Oncol; 2012 Sep; 30(5):596-601. PubMed ID: 21458314
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Resveratrol reduces the levels of circulating androgen precursors but has no effect on, testosterone, dihydrotestosterone, PSA levels or prostate volume. A 4-month randomised trial in middle-aged men.
    Kjaer TN; Ornstrup MJ; Poulsen MM; Jørgensen JO; Hougaard DM; Cohen AS; Neghabat S; Richelsen B; Pedersen SB
    Prostate; 2015 Sep; 75(12):1255-63. PubMed ID: 25939591
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oral exposure to low-dose bisphenol A aggravates testosterone-induced benign hyperplasia prostate in rats.
    Wu JH; Jiang XR; Liu GM; Liu XY; He GL; Sun ZY
    Toxicol Ind Health; 2011 Oct; 27(9):810-9. PubMed ID: 21415097
    [TBL] [Abstract][Full Text] [Related]  

  • 45. LHRH agonists. A nonsurgical treatment for benign prostatic hyperplasia.
    Oesterling JE
    J Androl; 1991; 12(6):381-8. PubMed ID: 1722794
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of a GnRH analogue (leuprolide) on benign prostatic hypertrophy.
    Gabrilove JL; Levine AC; Kirschenbaum A; Droller M
    J Clin Endocrinol Metab; 1987 Jun; 64(6):1331-3. PubMed ID: 2437142
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer.
    Morote J; Esquena S; Abascal JM; Trilla E; Cecchini L; Raventós CX; Catalán R; Reventós J
    Urol Int; 2006; 77(2):135-8. PubMed ID: 16888418
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serum sex hormones and measures of benign prostatic hyperplasia.
    Roberts RO; Jacobson DJ; Rhodes T; Klee GG; Leiber MM; Jacobsen SJ
    Prostate; 2004 Oct; 61(2):124-31. PubMed ID: 15305335
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy.
    Nejat RJ; Rashid HH; Bagiella E; Katz AE; Benson MC
    J Urol; 2000 Dec; 164(6):1891-4. PubMed ID: 11061874
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Testosterone Suppression with Luteinizing Hormone-Releasing Hormone (LHRH) Agonists in Patients Receiving Radiotherapy for Prostate Cancer.
    Wilke D; Patil N; Hollenhorst H; Bowes D; Rutledge R; Ago C
    Pharmacotherapy; 2018 Mar; 38(3):327-333. PubMed ID: 29337395
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Recovery of Serum Testosterone Levels and Sexual Function in Patients Treated With Short-term Luteinizing Hormone-releasing Hormone Antagonist as a Neoadjuvant Therapy Before External Radiotherapy for Intermediate-risk Prostate Cancer: Preliminary Prospective Study.
    Inoue T; Mizowaki T; Kabata D; Shintani A; Terada N; Yamasaki T; Negoro H; Kobayashi T; Nakamura K; Inokuchi H; Ogawa O
    Clin Genitourin Cancer; 2018 Apr; 16(2):135-141.e1. PubMed ID: 29051056
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serum inhibin--not a cause of low testosterone levels in hypogonadal prostate cancer?
    Lackner JE; Maerk I; Koller A; Bieglmayer C; Marberger M; Kratzik C; Schatzl G
    Urology; 2008 Nov; 72(5):1121-4. PubMed ID: 18407338
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of mepartricin on estradiol and testosterone serum levels and on prostatic estrogen, androgen and adrenergic receptor concentrations in adult rats.
    Re G; Badino P; Odore R; Vigo D; Bonabello A; Rabino S; Capello F; Bruzzese T
    Pharmacol Res; 2001 Aug; 44(2):141-7. PubMed ID: 11516265
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Resistance to apoptosis and up regulation of Bcl-2 in benign prostatic hyperplasia after androgen deprivation.
    Cardillo M; Berchem G; Tarkington MA; Krajewski S; Krajewski M; Reed JC; Tehan T; Ortega L; Lage J; Gelmann EP
    J Urol; 1997 Jul; 158(1):212-6. PubMed ID: 9186362
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rapid androgen cycling as treatment for patients with prostate cancer.
    Feltquate D; Nordquist L; Eicher C; Morris M; Smaletz O; Slovin S; Curley T; Wilton A; Fleisher M; Heller G; Scher HI
    Clin Cancer Res; 2006 Dec; 12(24):7414-21. PubMed ID: 17189414
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.
    Chertin B; Spitz IM; Lindenberg T; Algur N; Zer T; Kuzma P; Young AJ; Catane R; Farkas A
    J Urol; 2000 Mar; 163(3):838-44. PubMed ID: 10687989
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The relationship of prostate specific antigen levels and residual tumor volume in stage A prostate cancer.
    Carter HB; Partin AW; Epstein JI; Chan DW; Walsh PC
    J Urol; 1990 Nov; 144(5):1167-70; discussion 1170-1. PubMed ID: 1700143
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhibitory effects of Ponciri Fructus on testosterone-induced benign prostatic hyperplasia in rats.
    Jeon WY; Kim OS; Seo CS; Jin SE; Kim JA; Shin HK; Kim YU; Lee MY
    BMC Complement Altern Med; 2017 Aug; 17(1):384. PubMed ID: 28774334
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of Lespedeza Cuneata aqueous extract on testosterone-induced prostatic hyperplasia.
    Park BK; Kim CW; Kwon JE; Negi M; Koo YT; Lee SH; Baek DH; Noh YH; Kang SC
    Pharm Biol; 2019 Dec; 57(1):90-98. PubMed ID: 30724641
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.
    Andriole GL; Roehrborn C; Schulman C; Slawin KM; Somerville M; Rittmaster RS
    Urology; 2004 Sep; 64(3):537-41; discussion 542-3. PubMed ID: 15351586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.